Picture of Exousia Pro logo

MAJI Exousia Pro Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m-27.71%
3m-49.14%
6m+115.58%
1yr-5.7%
Volume Change (%)
10d/3m-65.37%
Price vs... (%)
52w High-63.24%
50d MA-30.87%
200d MA+41.8%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Apr 202130th Apr 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2021 / 2022

Blurred out image of Exousia Pro EPS forecast chart

Profile Summary

Exousia Pro, Inc., formerly Marijuana, Inc., is a clinical-stage biotechnology company, which is engaged in developing new ways to use the therapeutic potential of exosomes, initially focused on oncology. The Company's mammalian exosomal technology platform has shown the capability to increase the efficacy of Merck's drug Temozolomide (TMZ) in the treatment of glioblastoma (GBM). Its patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications from dermatology to dentistry. The Company's proprietary loading technology can infuse a range of molecules from drugs to deoxyribonucleic acid (DNA).

Directors

Last Annual
April 30th, 2020
Last Interim
January 31st, 2021
Incorporated
August 4th, 2023
Public Since
December 28th, 2010
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
35,094,567

MAJI Share Price Performance

Upcoming Events for MAJI

Similar to MAJI

Picture of Actavia Life Sciences logo

Actavia Life Sciences

us flag iconPink Sheets on Nasdaq

Picture of Acura Pharmaceuticals logo

Acura Pharmaceuticals

us flag iconPink Sheets on Nasdaq

Picture of Adhera Therapeutics logo

Adhera Therapeutics

us flag iconPink Sheets on Nasdaq

Picture of Ramoil Management logo

Ramoil Management

us flag iconPink Sheets on Nasdaq

Picture of Adynxx logo

Adynxx

us flag iconPink Sheets on Nasdaq

FAQ